VIVIMEDLAB2023-01-012023-03-31 VIVIMEDLAB2023-01-012023-03-31 VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member VIVIMEDLAB2023-03-31 VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentRevenue01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentRevenue02Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:FourReportableSegmentRevenue01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:FourReportableSegmentRevenue02Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentResults01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentResults02Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:FourReportableSegmentResults01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:FourReportableSegmentResults02Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentAssets01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentAssets02Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentLiabilities01Member VIVIMEDLAB2023-03-31in-bse-fin:OneReportableSegmentLiabilities01Member VIVIMEDLAB2023-01-012023-03-31in-bse-fin:OneReportableSegmentLiabilities02Member VIVIMEDLAB2023-03-31in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532660 VIVIMEDLAB na Vivimed Labs Limited Equity 2022-04-01 2023-03-31 2023-05-30 2023-05-18 INR Millions Yearly 16:00:00 23:10:00 2023-05-30 2023-05-30 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2023-01-01 2023-03-31 Audited Consolidated 370300000.00 6830000.00 377130000.00 227120000.00 590000.00 1592460000.00 88180000.00 85190000.00 959230000.00 104880000.00 3057650000.00 -2680520000.00 0.00 -2680520000.00 0.00 -20650000.00 -20650000.00 0.00 -2659870000.00 0.00 0.00 0.00 0.00 -2659870000.00 5590000.00 -2654280000.00 -2654280000.00 0.00 2654280000.00 0.00 165830000.00 2 -32.08 -31.14 0.00 0.00 -32.08 -31.14 NOTES 1. The above unaudited consolidated financial results of Vivimed Labs Limited ( the Company ) as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 30, 2023. The statutory auditors of the Company have carried out Audit on consolidated financial results and expressed an unmodified conclusion thereon. Multi segment 2022-04-01 2023-03-31 Audited Consolidated 1870990000.00 9680000.00 1880670000.00 1099520000.00 8010000.00 1607590000.00 326670000.00 359030000.00 1084070000.00 702290000.00 5187180000.00 -3306510000.00 0.00 -3306510000.00 0.00 -21170000.00 -21170000.00 0.00 -3285340000.00 0.00 0.00 0.00 0.00 -3285340000.00 5590000.00 -3279750000.00 -3279750000.00 0.00 3279750000.00 0.00 165830000.00 2 -142540000.00 -39.62 -38.46 0.00 0.00 -39.62 -38.46 Other Expenses 104880000.00 Other Expenses 702290000.00 0.00 2781750000.00 206650000.00 1988210000.00 0.00 0.00 1576400000.00 0.00 0.00 7580000.00 7580000.00 6560590000.00 797600000.00 0.00 768120000.00 37630000.00 0.00 397990000.00 606160000.00 1809900000.00 99190000.00 616180000.00 3322870000.00 9883460000.00 165830000.00 228400000.00 394230000.00 394230000.00 623190000.00 4423760000.00 5046950000.00 43810000.00 95150000.00 60320000.00 5246230000.00 3162470000.00 694130000.00 163910000.00 4020510000.00 27110000.00 12470000.00 182910000.00 4243000000.00 9489230000.00 9883460000.00 Pharma Business 317180000.00 Speciality Chemicals Business 59960000.00 Pharma Business 1768460000.00 Speciality Chemicals Business 112210000.00 377140000.00 1880670000.00 0.00 0.00 377140000.00 1880670000.00 Pharma Business -1488670000.00 Speciality Chemicals Business -1106650000.00 Pharma Business -1672970000.00 Speciality Chemicals Business -1274510000.00 -2595320000.00 -2947480000.00 85190000.00 359030000.00 0.00 Segmental capital employed As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangebility across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table. 0.00 -2680510000.00 -3306510000.00 Pharma Business 0.00 Speciality Chemicals Business 0.00 0.00 0.00 0.00 Pharma Business 0.00 Speciality Chemicals Business 0.00 0.00 0.00 0.00 359030000.00 1610060000.00 105540000.00 0.00 -31490000.00 0.00 0.00 31500000.00 0.00 275190000.00 0.00 -830000.00 0.00 1084070000.00 0.00 -32970000.00 0.00 44520000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3444620000.00 138110000.00 0.00 0.00 0.00 0.00 0.00 138110000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -9900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 196590000.00 0.00 0.00 0.00 0.00 359030000.00 0.00 0.00 -162440000.00 -34230000.00 0.00 -34230000.00 71840000.00 37610000.00 5590000.00 5590000.00 0.00 0.00 0.00 0.00